Form 4 for IDYA IDEAYA Biosciences, Inc.
Accepted 2024-05-16 00:00:00 ET · period of report 2024-05-14 · accession 0001610717-24-000239 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2024-05-16 | 2024-05-14+ | IDYA | Hata Yujiro S | Pres, CEO, Dir | S - Sale+OE | $42.27 | -175.0K | 682.2K | -20% | -$7.40M |
| DMT | 2024-05-16 | 2024-05-14+ | IDYA | Hata Yujiro S | Pres, CEO, Dir | M - OptEx | $4.31 | +175.0K | 761.7K | +30% | +$754.2K |
| DMT | 2024-05-16 | 2024-05-14+ | IDYA | Hata Yujiro S | Pres, CEO, Dir | M - OptEx | $0.00 | -175.0K | 83.9K | -68% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-05-16 | S | D | 4,349 | $42.37 | 677,887 | D | — | — | (F8) This transaction was executed in multiple trades in prices ranging from $42.26 to $42.595, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| 2 | Common | Common Stock | 2024-05-14 | M | A | 56,711 | $4.31 | 734,598 | D | — | — | |
| 3 | Common | Common Stock | 2024-05-14 | S | D | 54,408 | $41.60 | 680,190 | D | — | — | (F2) This transaction was executed in multiple trades in prices ranging from $40.815 to $41.80, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| 4 | Common | Common Stock | 2024-05-14 | S | D | 2,303 | $41.84 | 677,887 | D | — | — | (F3) This transaction was executed in multiple trades in prices ranging from $41.81 to $41.945, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| 5 | Common | Common Stock | 2024-05-15 | S | D | 53,592 | $42.57 | 708,151 | D | — | — | (F4) This transaction was executed in multiple trades in prices ranging from $42.08 to $43.07, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| 6 | Common | Common Stock | 2024-05-15 | S | D | 29,761 | $43.48 | 678,390 | D | — | — | (F5) This transaction was executed in multiple trades in prices ranging from $43.09 to $43.99, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| 7 | Common | Common Stock | 2024-05-15 | S | D | 503 | $44.12 | 677,887 | D | — | — | (F6) This transaction was executed in multiple trades in prices ranging from $44.10 to $44.14, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| 8 | Common | Common Stock | 2024-05-16 | M | A | 34,433 | $4.31 | 712,320 | D | — | — | |
| 9 | Common | Common Stock | 2024-05-16 | S | D | 30,084 | $41.73 | 682,236 | D | — | — | (F7) This transaction was executed in multiple trades in prices ranging from $41.2651 to $42.25, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| 10 | Common | Common Stock | 2024-05-15 | M | A | 83,856 | $4.31 | 761,743 | D | — | — | |
| 11 | Derivative | Stock Option (right to buy) | 2024-05-14 | M | D | 56,711 | $0.00 | 167,743 | D | $4.31 · — to 2028-02-26 | 56,711 Common Stock | (F9) The shares subject to the option are fully vested and exercisable. |
| 12 | Derivative | Stock Option (right to buy) | 2024-05-16 | M | D | 34,433 | $0.00 | 49,454 | D | $4.31 · — to 2028-02-26 | 34,433 Common Stock | (F9) The shares subject to the option are fully vested and exercisable. |
| 13 | Derivative | Stock Option (right to buy) | 2024-05-15 | M | D | 83,856 | $0.00 | 83,887 | D | $4.31 · — to 2028-02-26 | 83,856 Common Stock | (F9) The shares subject to the option are fully vested and exercisable. |